Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CTA018 cream, CTA018 Injection
CTA018 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| CTA018 Injection low dose | EXPERIMENTAL | Low dose IV 3 times a week for 4 weeks |
| CTA018 Injection low to mid dose | EXPERIMENTAL | low to mid dose IV 3 times a week for 4 weeks |
| CTA018 Injection mid to high dose | EXPERIMENTAL | mid to high dose IV 3 times a week for 4 weeks |
| CTA018 Injection high dose | EXPERIMENTAL | high dose IV 3 times a week for 4 weeks |
| Name | Type | Description |
|---|---|---|
| CTA018 Injection | DRUG | Comparison of different dosages of drug |
| CTA018 cream | DRUG | - |
Inclusion Criteria: * Body mass index between 18 and 35 * On maintenance hemodialysis three times per week * Serum iPTH value greater than or equal to 300 pg/mL and lower than or equal to 1000 pg/mL * Adjusted or total serum calcium value greater than or equal to 8.4 mg/dL and lower than 10.0 mg/dL...
Top 20 of 28 competitors
CTA018 is an investigational small molecule developed by Opko Health Inc. (ticker OPK) for chronic kidney disease and psoriasis. It has been studied in Phase 2 clinical trials, including one in Stage 5 chronic kidney disease and one in plaque psoriasis. It is not approved and remains in clinical development.
CTA018 has been studied in chronic kidney disease, specifically in a Phase 2 trial of CTA018 Injection to treat Stage 5 chronic kidney disease. That trial also enrolled patients with secondary hyperparathyroidism, chronic renal insufficiency, and chronic renal failure. CTA018 is investigational and has not been approved for any use.
CTA018 is developed by Opko Health Inc., which trades under the ticker OPK. Opko Health sponsored the Phase 2 clinical trials of CTA018 in chronic kidney disease and plaque psoriasis. No other developer or partner is identified for the program.
CTA018 is in Phase 2 development. Two Phase 2 trials have been completed: one in Stage 5 chronic kidney disease and one in plaque psoriasis. There are no active trials of CTA018, and the drug is investigational rather than approved.
CTA018 has been evaluated in two completed Phase 2 trials. NCT00742716 studied CTA018 Injection in Stage 5 chronic kidney disease across the United States and Canada. NCT00384098 studied topically applied CTA018 in plaque psoriasis in the United States. Neither trial is currently active.
Yes. CTA018 cream and CTA018 Injection are alternative names for CTA018, referring to different formulations of the same investigational small molecule from Opko Health Inc. The cream formulation was studied in plaque psoriasis, while the injection formulation was studied in Stage 5 chronic kidney disease.